Press coverage about Allergan (NYSE:AGN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan earned a news impact score of 0.02 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 49.1009353379647 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Vetr Downgrades Allergan (AGN) to Hold (americanbankingnews.com)
- Allergan (AGN) Upgraded at Vetr (americanbankingnews.com)
- Allergan: The Shire Deal Is DOA And So Is The Stock (seekingalpha.com)
- Allergan Declines to Bid on Shire (finance.yahoo.com)
- Shire rejects Takeda’s $62B cash, shares offer while Allergan steps in and out (bioworld.com)
A number of brokerages recently weighed in on AGN. Leerink Swann upped their price objective on Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. JPMorgan Chase set a $265.00 price objective on Allergan and gave the stock a “buy” rating in a report on Thursday, March 15th. Vetr lowered Allergan from a “buy” rating to a “hold” rating and set a $180.97 price objective on the stock. in a report on Wednesday, January 10th. Deutsche Bank reaffirmed a “buy” rating on shares of Allergan in a report on Thursday, April 12th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $191.00 price objective on shares of Allergan in a report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. Allergan currently has a consensus rating of “Hold” and a consensus target price of $220.91.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. During the same period in the prior year, the business earned $3.90 earnings per share. The business’s revenue was up 12.0% on a year-over-year basis. sell-side analysts anticipate that Allergan will post 15.59 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th were given a $0.72 dividend. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.82%. The ex-dividend date of this dividend was Tuesday, February 27th. Allergan’s dividend payout ratio is currently 17.61%.
In other Allergan news, CEO Brent L. Saunders bought 3,300 shares of Allergan stock in a transaction that occurred on Thursday, March 8th. The shares were purchased at an average cost of $152.53 per share, for a total transaction of $503,349.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Maria Teresa Hilado bought 895 shares of Allergan stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average price of $167.39 per share, for a total transaction of $149,814.05. The disclosure for this purchase can be found here. Insiders have purchased 8,095 shares of company stock worth $1,258,081 over the last quarter. 0.36% of the stock is currently owned by company insiders.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.